Eltrombopag ethanolamine tablets should be taken at the lowest dose that results in a platelet count of ≥50,000/μL being achieved and maintained, with a recommended initial dose of 25 mg. Eltrombopag olamine tablets are an oral small molecule thrombopoietin receptor agonist that interacts with the human thrombopoietin receptor to initiate the relevant response and induce platelet production. The drug is used in adult patients with chronic immune thrombocytopenia who do not respond well to treatment with glucocorticoids and immunoglobulins. Eltrombopag olamine tablets are used at the lowest dose that achieves and maintains a platelet count of ≥50,000 μL, with a recommended initial dose of 25 mg and dose adjustments based on the response of platelet counts to the drug. The drug needs to be taken on an empty stomach and should not be taken with food and fluids, antacids, or dairy products. The drug may cause headache, anemia, loss of appetite, insomnia, cough and other discomforts, and is contraindicated in those who are allergic to Eltrombopag ethanolamine or any of the excipients. If you need to use the drug, please use under the guidance of a physician, do not self-medication, if you take the drug after the discomfort, please go to the hospital in time to check the medical care.